Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Chloride SCHEMBL28130449 | 0.92 | PGR (0.37) | PGRAR | |
| SCHEMBL16554098 | 0.84 | CA2 (0.35) | PGRARCES1CA2SRC | |
| SCHEMBL27729592 | 0.82 | CES1 (0.35) | CES1CA2MLYCD | |
| SCHEMBL28755812 | 0.82 | CES1 (0.31) | CES1CA2 | |
| SCHEMBL10031827 | 0.82 | PGR (0.47) | PGRARCES1L3MBTL1ELANE | |
| SCHEMBL27390852 | 0.80 | CES1 (0.36) | CES1CA2 | |
| SCHEMBL9053187 | 0.79 | RIPK1 (0.36) | MLYCD | |
| SCHEMBL9787049 | 0.77 | POLB (0.36) | MLYCD | |
| SCHEMBL608510 | 0.76 | CES1 (0.60) | CES1MLYCD | |
| SCHEMBL10665081 | 0.76 | ALDH1A1 (0.33) | CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0463989-B1 | N-oxyimidic acid derivatives | SANDOZ LTD (CH) | 1994-12-28 | — | — | EP | claimed |
| US-5319123-A | Reacting an N-alkoxyamide with an acyl halide in the presence of a hindered base | SANDOZ LTD. (CH) | 1994-06-07 | — | — | US | claimed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | claimed |
| EP-0463989-A1 | N-oxyimidic acid derivatives | SANDOZ LTD. (CH) | 1992-01-02 | — | — | EP | claimed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023282236-A1 | RARE EARTH COMPLEX | 東ソー株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (UK) | 2016-02-25 | — | — | US | disclosed |
| EP-2978316-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | Syngenta Participations AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0463989-A1 | N-oxyimidic acid derivatives | SANDOZ LTD. (CH) | 1992-01-02 | — | — | EP | disclosed |
| EP-0192167-A1 | Use of thio-substitued ketones as photoinitiators | MERCK PATENT GmbH (DE) | 1986-08-27 | — | — | EP | disclosed |
| EP-0038614-A2 | Esters of 5- and 6-oxo-prostaglandins | THE UPJOHN COMPANY (US) | 1981-10-28 | — | — | EP | disclosed |
| US-4211879-A | Esters of prostacyclin-type compounds | THE UPJOHN COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4180657-A | Acyl-substituted phenyl esters of prostacyclin-type compounds | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | DDT, CRY1, NISCH | PGR 3761/4885AR 4129/4885CES1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.